Obinutuzumab Superior to Rituximab for Previously Untreated Follicular Lymphoma

Share this content:
Obinutuzumab was superior to rituximab with respect to progression-free survival in patients with previously untreated follicular lymphoma.
Obinutuzumab was superior to rituximab with respect to progression-free survival in patients with previously untreated follicular lymphoma.

When combined with chemotherapy, obinutuzumab was superior to rituximab with respect to progression-free survival in patients with previously untreated follicular lymphoma, preliminary data from the phase 3 GALLIUM trial has shown.1

For the multicenter, open-label study, researchers enrolled 1401 patients with previously untreated indolent non-Hodgkin lymphoma, of which 1202 patients had follicular lymphoma. Participants were randomly assigned to receive chemotherapy (CHOP, CVP, or bendamustine) with obinutuzumab followed by obinutuzumab alone, or chemotherapy plus rituximab followed by rituximab alone.

Results from a preplanned interim analysis show that obinutuzumab-based treatment significantly improve progression-free survival in contrast with rituximab-based treatment. Safety profiles were consistent with previous studies.

"People with follicular lymphoma continue to need better initial treatment options because their disease is incurable and becomes more difficult to treat with each relapse," said Sandra Horning, MD, chief medical officer and head of Global Product Development for Genentech. "GALLIUM is the second study in which [obinutuzumab] showed superior progression-free survival compared to [rituximab], when each was combined with chemotherapy."

In the first head-to-head trial between obinutuzumab and rituximab, patients with previously untreated chronic lymphocytic leukemia (CLL) experienced a longer progression-free survival with obinutuzumab plus chlorambucil compared with rituximab plus chlorambucil.

RELATED: GnRHa Not Efficient In Preventing Premature Ovarian Failure in Lymphoma

In addition to being approved for the treatment of patients with previously untreated CLL, obinutuzumab is indicated for the treatment of relapsed/refractory follicular lymphoma, in combination with bendamustine, after a rituximab-containing regimen.    

Reference

  1. Genentech's Gazyva showed superior progression-free survival compared to Rituxan in people with previously untreated follicular lymphoma.  Genentech. http://www.gene.com/media/press-releases/14628/2016-05-26/genentechs-gazyva-showed-superior-progre. Published May 26, 2016. Accessed May 27, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters